AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02294396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
Study NCT02294396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propiverine tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
Study NCT02294396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidafenacin tablet
Description: orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
Study NCT01437163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TopHat 655 rejuvenation system
Description: TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
Study NCT01437163 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser and/or Light Hair Rejuvenation System
Description: A red incandescent light source replaces all lasers and light emitting diodes.
Study NCT01356680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)
Study NCT01356680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)
Study NCT01356680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
Study NCT01356680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
Study NCT01356680 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 30Gy IF-RT (Involved-Field Radiotherapy)
Study NCT01356680 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30Gy IN-RT (Involved-Node Radiotherapy)
Study NCT00265135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
Study NCT05660590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complex decongestive physiotherapy with low pressure compression bandage
Description: both group received complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with low bandage interface pressure (20-30 mmHg)
Study NCT05660590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complex decongestive physiotherapy with high pressure compression bandage
Description: complex decongestive physiotherapy consist of manual lymph dranaige, skin care, exercise and compression bandage. Every component except compression bandage applied exacly the same to both group. Compression bandage applied with high bandage interface pressure (45-55 mmHg)
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT516
Description: Experimental Interventional Therapy
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Monoclonal Antibody
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Conditioning agent
Study NCT02294396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine capsule
Description: orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning agent
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Biologic response modifier
Study NCT04023071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Conditioning agent
Study NCT02765919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy of 9 Gy in 2 fractions
Description: Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
Study NCT02765919 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HDR Brachytherapy of 7 Gy in 3 fractions
Description: Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
Study NCT03680625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive Distraction
Description: Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal and/or removal of sutures. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
Study NCT03680625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Patients in this group will be offered virtual reality distraction through the use of Oculus Quest® while they undergo their pins' removal and/or removal of sutures. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus head-mounted device and computer will be available in the procedure room and ready for immediate use. The head-mounted device will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin and/or suture removal in order for the child to get acquainted with the game and immersed in the virtual environment.
Study NCT02964676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ab interno trabeculectomy with Trabectome
Description: 123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
Study NCT02964676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculectomy
Description: 123 PACG will be recruited to receive trabeculectomy to reduce IOP
Study NCT00811382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)
Description: Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
Study NCT00811382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)
Description: Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
Study NCT01135433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT00766675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Study NCT00766675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Study NCT01746095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin hydrochloride inhalation powder
Description: There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
Study NCT01746095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder
Study NCT01575353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
Study NCT01575353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high-flow
Description: The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
Study NCT00883506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 40 mg Tablet (Zestril) under fed conditions.
Study NCT00883506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg Tablet under fasting conditions.
Study NCT00883506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg Tablet under fed conditions.
Study NCT03099330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: TQ-B3139 p.o. qd
Study NCT04606784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Ampion, nebulized for inhalation
Study NCT04606784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care
Study NCT04606784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care
Study NCT01925664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doula
Description: This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
Study NCT03404492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stress echocardiography
Description: A stress echocardiography will be performed in addition to the traditional patient care
Study NCT03075384 — intervention group
Intervention type: PROCEDURE
Intervention: computer-assisted navigation system
Description: The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
Study NCT03041779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 50Mg Suppository
Study NCT03041779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500Mg Suppository
Study NCT02044848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Study NCT02044848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01135433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01135433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral
Study NCT01135433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: oral
Study NCT04386434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active for Life: Assisted Living
Description: Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last \~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between.
Study NCT05570643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS
Description: This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
Study NCT05570643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of NaCl 0.9%.
Study NCT04432831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
Study NCT04432831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
Study NCT00501189 — intervention group
Intervention type: BIOLOGICAL
Intervention: human papillomavirus vaccine L1, type 6,11,16,18
Description: Subjects are those getting gradasil vaccination already. This is really not an intervention
Study NCT06526403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy ASD closure
Description: Percutaneous ASD closure without fluoroscopy was performed in secundum-type oval-shaped ASD
Study NCT00539279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Description: PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
Study NCT00539279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training (RT)
Description: RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
Study NCT01561859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
Study NCT01561859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis.
Study NCT02834156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LP in a seated position then LP in a lying position
Study NCT02834156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LP in a lying position then LP in a seated position
Study NCT01316094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01316094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study NCT03909334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib 80 mg orally on Day 1
Study NCT03909334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes
Study NCT00977314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Sonitus Bone Conduction Hearing System
Description: Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
Study NCT00977314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite
Study NCT00977314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System
Study NCT02173678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBIVENT® HFA-MDI
Study NCT02173678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBIVENT® CFC-MDI
Study NCT02173678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HFA-MDI
Study NCT03064815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videocapsule endoscopy
Description: Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures.
Study NCT03064815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
Study NCT03064815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PROMETHEUS® IBD sgi Diagnostic™
Description: This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
Study NCT03314389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet bonnet esthesiometer
Description: Cochet bonnet esthesiometer- To examine sensation
Study NCT02923466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intratumoral injection of a single dose of VSV-IFNβ-NIS
Study NCT02923466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS and avelumab
Description: Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
Study NCT03044158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GeneXpert I
Description: Onsite molecular testing with GeneXpert I as a replacement for microscopy
Study NCT03044158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process re-design
Description: Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
Study NCT03044158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance Feedback
Description: Feedback of TB diagnostic evaluation quality indicators to health center staff
Study NCT00801190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HES (130/0.4)
Description: 33 ml/kg i.v. during surgery
Study NCT00801190 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Lactate
Description: 33 ml/kg i.v.
Study NCT00322400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.